[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:chronic-hepatitis-b":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":66,"states":75},"Chronic Hepatitis B",9,8,[8,16,22,29,35,41,47,53,59],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06092333","VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B",[12],"Phase 2","RECRUITING","2026-08-26T02:19:05.360997Z","2026-07-24T01:27:14.928202Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06963710","A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)",[12],"2026-08-03T01:56:45.025842Z","2026-05-05T02:43:28.740314Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT07342881","Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function",[26],"Phase 1","2026-08-03T02:19:01.379791Z","2026-05-05T02:43:27.956228Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT07342868","Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function",[26],"2026-08-03T02:54:41.410572Z","2026-05-05T02:43:27.063308Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT07654283","Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions",[12],"2026-08-26T02:16:39.977107Z","2026-06-17T19:21:16.688868Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT06277037","Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)",[],"2026-08-26T02:18:46.137046Z","2026-05-13T02:55:06.430679Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT05181826","Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer",[],"2026-08-26T02:16:24.970704Z","2026-07-19T19:36:05.131295Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":57,"content_modified":58},"NCT06154278","Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B",[12],"2026-08-26T02:19:13.549512Z","2026-05-05T02:43:27.958288Z",{"nct_id":60,"title":61,"phases":62,"status":63,"updated_at":64,"content_modified":65},"NCT07254208","A Long-term Observational Study in Participants Who Have Received PBGENE-HBV",[],"ENROLLING_BY_INVITATION","2026-08-26T02:16:41.943926Z","2026-06-16T05:54:07.874883Z",[67,71],{"biomarker":68,"count":69,"slug":70},"Hepatitis B Virus HBsAg Surface Protein Antigen",4,"hepatitis-b-virus-hbsag-surface-protein-antigen",{"biomarker":72,"count":73,"slug":74},"Hepatitis B Infection",3,"hepatitis-b-infection",[76,79,82],{"state":77,"count":69,"slug":78},"California","california",{"state":80,"count":69,"slug":81},"Florida","florida",{"state":83,"count":69,"slug":84},"Maryland","maryland"]